Health committee  I would be happy to answer that, Madam Chair. I think that Dr. Bourguet, in describing the explosion of research in this area, reflects the importance of what the nuclear medicine community can do in terms of assisting our clinical colleagues as they make important clinical deci

Health committee  I'll agree to disagree with my colleague. I do think this is a very important initiative, looking to the short to medium term, and I believe we will see benefits from it.

Health committee  Madam Chair, again, I'd like to remind the committee that this is a report from NRCan. It is not from Health Canada. I would love to be able to answer that question, because I suspect that, of everybody in this room, I would like to see it the most. I'm sorry I can't give you any

Health committee  My understanding is that they have some confidence that they will meet the quarter-one expectations.

Health committee  AECL will let us know as soon as they have some confidence that their repair methodologies are working. My immediate action now is to look at the medium term and plan for the worst-case scenario. So that is what I am doing with my colleagues at the moment.

Health committee  Thank you, Madam Chair. I'd like to agree with Chris wholeheartedly. I think this issue around technetium supply in many ways has shown the value of nuclear medicine to our patients now, but more importantly, it is enabling us to redefine how we will practise in the future. I th

Health committee  Certainly, Madam Chair. It would be a pleasure to address that. I think the CIHR initiative is an extremely important initiative in looking at ways of ensuring that this crisis does not continue longer than it has to, if we continue to have disruptions of technetium supply. Of

Health committee  Those data have been requested from the provincial governments. They have not yet been given to us.

Health committee  I can tell you anecdotally that I have discussed it with colleagues on the ground in individual institutions. There is quite a range in the increasing costs noted. One centre, for example, has said that they are seeing an increase of between $8 to $12 per dose.

Health committee  My understanding is that health care delivery is a provincial role. I will remind you that this issue was raised at a recent federal-provincial-territorial ministers meeting. The data have been requested. Once the data have been received, we can understand what those real costs a

Health committee  I am afraid I do not belong to the government. I cannot answer for those questions. All I can say is that I do intend to understand what the cost implications are. Once I understand those, I can have an appropriate conversation.

Health committee  Madam Chair, I know that it is being received on November 30. I do not understand or know enough about parliamentary procedure to know whether I can answer that question. I assume that it will be released when it can be.

Health committee  There are two routes of communication that happen regularly. There is the federal-provincial-territorial meeting, which occurs weekly, at which data is shared. We have the meeting of the experts working group, which involves both the Canadian Association of Nuclear Medicine and t

Health committee  Madam Chair, I would like to remind you that I am not the federal government. I'm an adviser to the minister, and therefore I cannot answer a question like that.

Health committee  Those centres were in Vancouver, Alberta, Manitoba, and the Atlantic provinces. Dr. Lamoureux from Quebec is on record in the press as saying that there has been no significant change in referral patterns in Quebec. In my conversations with Dr. Tracey, he indicated that he is see